David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images)
August 4, 2022 01:38 PM EDTUpdated August 5, 09:34 AM
Pharma

Eli Lil­ly CEO Ricks echoes a grow­ing re­frain on price ne­go­ti­a­tions: 'We’ll fo­cus our re­sources on oth­er ar­eas'

John Carroll

Editor & Founder

Eli Lil­ly had some drea­ry Q2 num­bers to re­port Thurs­day. And they kept an­a­lysts and in­vestors on hold for an hour be­fore at­tempt­ing an ex­pla­na­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times